Kolon Life Science (102940.KQ) Stock Price

KOLON Life Science, Inc. generates revenue through its Chemical Business segment, which produces and sells raw drug products, antibacterial agents, water treatment agents, and functional material products for cosmetics. The Bio Business segment focuses on manufacturing and selling bio new medicines based on cell gene therapy products. The company's products target pharmaceutical and environmental markets, with raw drug products serving as essential components for new and generic drugs, while antibacterial agents and water treatment agents address healthcare and environmental purification needs. Functional materials for cosmetics represent a key product line within the Chemical Business segment. The company's revenue streams are derived from the sale of pharmaceutical raw materials, antibacterial agents, water treatment solutions, and cosmetic functional materials under the Chemical Business segment. The Bio Business segment contributes through the commercialization of advanced cell gene therapy-based medicines. Both segments operate within the pharmaceutical and environmental sectors, with the Chemical Business serving as the primary revenue driver for raw materials and environmental products, while the Bio Business targets innovative therapeutic solutions in the biopharmaceutical space. KOLON Life Science, Inc. sells its products to the pharmaceutical industry for drug development and manufacturing, as well as to environmental and cosmetic companies requiring specialized materials. The Chemical Business segment's raw drug products are used by pharmaceutical firms to produce new and generic drugs, while antibacterial agents and water treatment agents are supplied to healthcare and environmental purification sectors. Cosmetic functional materials are sold to the cosmetics industry for product development. The Bio Business segment's cell gene therapy products are targeted at biopharmaceutical companies seeking advanced treatment options.